Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies (Q37832570)

24 August 2017

1 reference

title

Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies (English)

1 reference

24 August 2017

Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies (English)

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

23 November 2024

0 references

1 reference

stem cell transplantation

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

Sebastian Böttcher

1 reference

24 August 2017

Matthias Ritgen

series ordinal

1 reference

24 August 2017

Peter Dreger

series ordinal

1 reference

24 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21269744

23 November 2024

publication date

26 January 2011

1 reference

full work available at URL

24 August 2017

1 reference

inferred from page(s)

https://api.elsevier.com/content/article/PII:S0268960X11000026?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

https://api.elsevier.com/content/article/PII:S0268960X11000026?httpAccept=text/plain

23 November 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

23 November 2024

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

91-96

1 reference

How I treat refractory CLL.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Treatment of fludarabine-refractory chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Genomic aberrations and survival in chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

TP53 mutation and survival in chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry.

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q- and 17p-)

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Allotransplantation for chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

23 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.BLRE.2011.01.001

23 November 2024

Identifiers

1 reference

24 August 2017

1 reference